1
|
Spiess D, Abegg VF, Chauveau A, Rath J, Treyer A, Reinehr M, Kuoni S, Oufir M, Potterat O, Hamburger M, Simões-Wüst AP. Transplacental passage of hyperforin, hypericin, and valerenic acid. Front Pharmacol 2023; 14:1123194. [PMID: 37063288 PMCID: PMC10103840 DOI: 10.3389/fphar.2023.1123194] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 03/20/2023] [Indexed: 04/03/2023] Open
Abstract
Safe medications for mild mental diseases in pregnancy are needed. Phytomedicines from St. John’s wort and valerian are valid candidates, but safety data in pregnancy are lacking. The transplacental transport of hyperforin and hypericin (from St. John’s wort), and valerenic acid (from valerian) was evaluated using the ex vivo cotyledon perfusion model (4 h perfusions, term placentae) and, in part, the in vitro Transwell assay with BeWo b30 cells. Antipyrine was used for comparison in both models. U(H)PLC-MS/MS bioanalytical methods were developed to quantify the compounds. Perfusion data obtained with term placentae showed that only minor amounts of hyperforin passed into the fetal circuit, while hypericin did not cross the placental barrier and valerenic acid equilibrated between the maternal and fetal compartments. None of the investigated compounds affected metabolic, functional, and histopathological parameters of the placenta during the perfusion experiments. Data from the Transwell model suggested that valerenic acid does not cross the placental cell layer. Taken together, our data suggest that throughout the pregnancy the potential fetal exposure to hypericin and hyperforin – but not to valerenic acid – is likely to be minimal.
Collapse
Affiliation(s)
- Deborah Spiess
- Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Vanessa Fabienne Abegg
- Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Antoine Chauveau
- Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Joshua Rath
- Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Andrea Treyer
- Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Michael Reinehr
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Sabrina Kuoni
- Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Mouhssin Oufir
- Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Olivier Potterat
- Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Matthias Hamburger
- Division of Pharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
- *Correspondence: Matthias Hamburger, ; Ana Paula Simões-Wüst,
| | - Ana Paula Simões-Wüst
- Department of Obstetrics, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- *Correspondence: Matthias Hamburger, ; Ana Paula Simões-Wüst,
| |
Collapse
|
2
|
Jiao M, Liu X, Ren Y, Wang Y, Cheng L, Liang Y, Li Y, Zhang T, Wang W, Mei Z. Comparison of Herbal Medicines Used for Women's Menstruation Diseases in Different Areas of the World. Front Pharmacol 2022; 12:751207. [PMID: 35185533 PMCID: PMC8854496 DOI: 10.3389/fphar.2021.751207] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2021] [Accepted: 12/16/2021] [Indexed: 12/27/2022] Open
Abstract
Aims: This review aims to compare the use of herbal medicine used to treat women's menstruation and the prevalence of menstrual diseases in different regions, which reveal the use of herbal medicine globally and provide scientific guidance for improving women's health. Materials and Methods: The information available on herbal medicines for women between the years 2000 and 2021 was systematically collected via the library and electronic search systems such as Google Scholar, PubMed, ScienceDirect, and Web of Science as well as secondary resources including books and conference proceedings. Results: Totally, 571 ethnic medicines commonly used for women's menstruation health in Asia, Europe, Oceania, Africa, and America were accounted. Zingiber officinale Roscoe (Ginger), Ruta graveolens L. (Common rue), Angelica sinensis (Oliv.) Diels (Angelica sinensis), Foeniculum vulgare Mill (Fennel), Catharanthus roseus (L.) G. Don (Catharanthus roseus) and other medicines which have obvious advantages and long-term usage are utilized in the treatment of menstrual diseases. Family Asteraceae, Lamiaceae, Apiaceae, Fabaceae, and Zingiberaceae are the most common medicinal plant families used for such treatments. In many instances, the application of fresh parts of plants was observed because of the healers' belief regarding the higher efficiency of the medicine made from fresh plants. Edible plants are used in a wide range of countries. Conclusion: Women's menstruation health is directly related to their health condition. Traditional medicines of most ethnic groups have contributed to women's health care and treatment of gynecological diseases. Practitioners in this field have gained elaborate experience in treatments and medication, and assembled a large number of effective drugs and prescriptions. These experiences have also been inherited and developed by modern clinical application and scientific research. However, the basic research on these drugs is not sufficient, the knowledge of drug use has not been fully popularized, the advantages of drugs have not been fully utilized, and the guiding potential to modern drug research continues to be insufficient. As such, it is necessary to further promote and make a significant contribution to women's health.
Collapse
Affiliation(s)
| | | | - Yongshen Ren
- School of Pharmacy, South-Central University for Nationalities, Wuhan, China
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Villar-López M, Soto-Becerra P, Curse Choque R, Al-Kassab-Córdova A, Bernuy-Barrera F, Palomino H, Rojas PA, Vera C, Lugo-Martínez G, Mezones-Holguín E. Safety and tolerability of a natural supplement containing glucosinolates, phytosterols and citrus flavonoids in adult women: a randomized phase I, placebo-controlled, multi-arm, double-blinded clinical trial. Gynecol Endocrinol 2021; 37:906-913. [PMID: 34379025 DOI: 10.1080/09513590.2021.1960965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
OBJECTIVE To evaluate the safety and tolerability of an oral herbal supplement containing glucosinolates, phytosterols, and citrus flavonoids (Warmi®, Lima Perú;) in otherwise healthy adult women. METHODS This was a phase-I, randomized parallel three arms, double-blinded, and a placebo-controlled clinical trial. A total of 55 participants aged 18-40 were randomly assigned to one of three groups to receive for three months: (1) an oral herbal supplement of 1650 mg/day; (2) an oral herbal supplement of 3300 mg/day; or (3) an oral placebo 3300 mg/day. The primary endpoints were oral safety and tolerability of the supplement. The secondary endpoint was its effect on vital functions, anthropometrics, and laboratory tests. We used an exploratory approach by covariance analysis (ANCOVA) adjusted for the variables' baseline value for the secondary outcomes. RESULTS All women completed three months of follow-up, reporting no side effects. Our exploratory analysis revealed that treatment with the herbal supplement of 1650 mg/day was associated with increased glucose and uric acid levels. In comparison, the herbal supplement 3300 mg/day was associated with reduced breathing rate, increased basal temperature, and systolic blood pressure, both compared to the placebo group. However, despite significant differences, none of these was clinically significant. CONCLUSION The oral herbal supplement had a favorable safety and tolerability profile in studied women. There is a need to study its potential as an option to treat menopausal symptoms.
Collapse
Affiliation(s)
- Martha Villar-López
- Universidad Nacional Mayor de San Marcos, Facultad de Medicina "San Fernando", Departamento de Medicina Preventiva y Salud Pública, Lima, Perú
| | - Percy Soto-Becerra
- Universidad San Ignacio de Loyola, Centro de Excelencia en Investigaciones Económicas y Sociales en Salud, Lima, Perú
- Epi-gnosis Solutions, Piura, Perú
| | - Ruth Curse Choque
- Hospital Carlos Alcántara Butterfield, Servicio de Pediatría, Lima, Perú
| | - Ali Al-Kassab-Córdova
- Universidad Peruana de Ciencias Aplicadas, Facultad de Ciencias de la Salud, Lima, Perú
| | - Félix Bernuy-Barrera
- Universidad Nacional Federico Villarreal, Facultad de Medicina Hipólito Unanue, Lima, Perú
| | - Henry Palomino
- Hospital Nacional Edgardo Rebagliati Martins, Departamento de Obstetricia y Ginecología, Lima, Perú
| | - Percy A Rojas
- Universidad Peruana Cayetano Heredia, Laboratorios de Investigación y Desarrollo, Unidad de Biotecnología Molecular, Lima, Perú
| | - Carmela Vera
- Hospital Nacional Edgardo Rebagliati Martins Lima, Servicio de Psicología, Perú
| | - Gabriela Lugo-Martínez
- Instituto Politécnico Nacional, Escuela Superior de Medicina, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México
| | - Edward Mezones-Holguín
- Universidad San Ignacio de Loyola, Centro de Excelencia en Investigaciones Económicas y Sociales en Salud, Lima, Perú
- Epi-gnosis Solutions, Piura, Perú
| |
Collapse
|
4
|
Abo-Gaida AAH, Halawa E, Abd-Elmootaal MR, Taha SM, Amer ME, Fernandez-Alba AR. Sample processing and preparation optimisation with three different solvents for the residual analysis of 310 pesticides in three herbal plants by LC-MS/MS. INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY 2021:1-18. [DOI: 10.1080/03067319.2021.1941917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 06/05/2021] [Indexed: 09/01/2023]
Affiliation(s)
- Abd-Alrahman H. Abo-Gaida
- Agricultural Research Center, Central Laboratory of Residue Analysis of Pesticides and Heavy Metals in Foods (QCAP Egypt), Dokki, Egypt
| | - Ekramy Halawa
- Agricultural Research Center, Central Laboratory of Residue Analysis of Pesticides and Heavy Metals in Foods (QCAP Egypt), Dokki, Egypt
| | - Mohamed R. Abd-Elmootaal
- Agricultural Research Center, Central Laboratory of Residue Analysis of Pesticides and Heavy Metals in Foods (QCAP Egypt), Dokki, Egypt
| | - Sherif M. Taha
- Agricultural Research Center, Central Laboratory of Residue Analysis of Pesticides and Heavy Metals in Foods (QCAP Egypt), Dokki, Egypt
| | - Mohamed E. Amer
- Agricultural Research Center, Central Laboratory of Residue Analysis of Pesticides and Heavy Metals in Foods (QCAP Egypt), Dokki, Egypt
| | - Amadeo R. Fernandez-Alba
- University of Almeria,European Union Reference Laboratory for Pesticide Residues in Fruits & Vegetables,Agrifood Campus of International Excellence (Ceia3), Almeria, Spain
| |
Collapse
|